BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture

Stock Information for BioSig Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioSig Technologies Inc.

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent  
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
BioSig Engages Consulting Firm for Business Model Strategies
BioSig Announces Reduction of its Workforce
BioSig's PURE EP(TM) Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
BioSig Announces Reverse Stock Split
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.